Clinical experience with BCG alone versus BCG plus epirubicin

International Journal of Urology

Volumn 7, Issue 6, 2000, Pages 206-209

  Bilen, Cenk Yücel ^a   Özen, Haluk ^a   Aki, Fazil Tuncay ^a   Aygün, Cem ^a   Ekici, Sinan ^a   Kendi, Sezer ^a  

^a Department of Urology ^*  (Turkey)

Author keywords

Bladder cancer; Intravesical chemotherapy; Intravesical immunotherapy

Indexed keywords

BCG VACCINE; EPIRUBICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER CONTRACTION; BLADDER IRRITATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEMATURIA; HEPATITIS; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; MALAISE; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0034080832     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00176.x     Document Type: Article

References (13)

1. 1 Lamm DL, Thor DE, Stodgill VD, Radwin HM. Bladder cancer immunotherapy. J. Urol. 1982; 128: 931-5.
2. 2 Camacho F, Pinsky CM, Kerr D, Whitmore WF, Oettgen HF. Treatment of superficial bladder cancer with intravesical BCG immunotherapy. In: Terry WT, Rosenberg SA (eds). Immunotherapy of Human Cancer. Elsevier, New Holland, 1982; 309.
3. 3 Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR. Superficial bladder cancer: The response of a marker tumour to a single intravesical instillation of epirubicin. Br. J. Urol. 1994; 74: 195-9.
4. 4 Herr HW, Laudone VP, Whitmore WF Jr. An overview of intravesical therapy for superficial bladder tumors. J. Urol. 1987; 138: 1363-8.
5. 5 Martinez-Pineiro JA, Jimenez-Leon J, Martinez-Pineiro L Jr et al. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990; 143: 502-7.
6. 6 Lamm DL. Immunotherapy versus chemotherapy in the treatment of the superficial bladder cancer. In: Bloom HFK, Hanham IWF (eds). Urology Oncology: Dilemmas and Developments. John Wiley, Chichester, 1988: 107-17.
7. 7 Calais da Silva F, Denis L, Bono A, Bollack C, Bouffioux C. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors. Eur. Urol. 1988; 14: 207-9.
8. 8 Kurth KH, Mross K, Ten Kate F et al. Phase I II study of intravesical epirubicin in patients with carcinoma in situ of the bladder. In: Uro-Oncologv: Current Status and Future Trends. Wiley-Liss, New York, 1990; 41.
9. 9 Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibrinonectin in intravesical BCG therapy for superficial bladder cancer. J. Urol. 1988; 139: 410-4.
10. 10 Hudson MA, Brown EJ, Ritchey JK, Ratliff TL. Modulation of fibrinonectin-mediated BCG attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 1991; 51: 3726-32.
11. 11 Serreta V, Pavone C, Corselli G, Pavone-Macaluso M. A pilot study comparing different dose levels and administration schedules of interferon-alpha-2b combined with epirubicin for prevention of recurrence in bladder cancer. Anticancer Drugs 1992; 3(Suppl.): 19-23.
12. 12 Ferrari P, Castagnetti G, Pollastri CA, Ferrari G, Tavoni F, Grassi D. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: Interferonalpha 2b versus interferon-alpha-2b with epirubicin. Anticancer Drugs 1992; 3(Suppl.): 25-7.
13. 13 Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O. Alternating mitomycin C and BCG instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J. Urol. 1996; 156: 56-60.